Skip to main content
CORT logo

Corcept Therapeutics Incorporated (CORT) Stock: Price, Forecast & Analyst Target

Corcept Therapeutics Incorporated (CORT) — MoonshotScore 91/100 (Exceptional band), calculated Nov 18, 2026. Price $67.79 (-3.25%), as of the Nov 18, 2026 trading session; market cap $7.42B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 20.02× (cash as of Sep 30, 2026) · expected results Feb 23, 2027

$67.79 −$2.28 (-3.25%) Market Cap $7.42B

Corcept Therapeutics Incorporated · CORT · NASDAQ · Healthcare · Medical - Pharmaceuticals

Research dated 2026-09-13: Corcept Therapeutics sells Korlym for hypercortisolism in adults with Cushing’s syndrome while developing selective cortisol modulators for endocrine and oncology uses. The equity story depends on whether Korlym can sustain expanding commercial spending and pipeline investment until relacorilant becomes a meaningful complement, while a demanding valuation already anticipates substantial growth.

Price as of Nov 18, 2026

Key Statistics

91 of 100

MoonshotScore v2 · Corcept Therapeutics (CORT)

Exceptional
Business Quality Elite (93)
Financial Safety Fortress (96)
Valuation Rich (38)
Growth Durability Compounding (82)
Momentum Quiet (56)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and durable growth, but an expensive valuation. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Quiet.

  • EPS beat 3 of the last 8 reports
  • Altman Z 25.80 · Piotroski F 6
  • ROE 22.1% · ROA 7.5% · current ratio 3.00

Helping: business quality, balance-sheet strength, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CORT (57 recorded, newest six shown)
RecordedScoreBand
86Exceptional
86Exceptional
85Exceptional
85Exceptional
91Exceptional
91Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$67.79
Change on the day-3.25%
52-week range$28.66–$126.38
Market capitalisation$7.42B—
Price / earnings (trailing)46.71
Shares traded on the day744.8K
Beta (volatility vs the S&P 500)0.45

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $32, high $122, latest $68. 4 reported quarters marked, 2 above and 2 below the recorded estimate. 1 other dated event marked. $122 $32 high $122 Feb 24, 2026 · Earnings results · reported below the recorded estimate · close $361Apr 30, 2026 · Earnings results · reported below the recorded estimate · close $512Jul 29, 2026 · Earnings results · reported above the recorded estimate · close $1143Nov 3, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $734Nov 3, 2026 · Earnings results · reported above the recorded estimate · close $735 Oct 17, 2025 Nov 18, 2026 · $68 $79Oct 17, 2025$73Oct 31, 2025$76Nov 14, 2025$79Nov 28, 2025$88Dec 12, 2025$83Dec 26, 2025$38Jan 9, 2026$44Jan 23, 2026$41Feb 6, 2026$35Feb 20, 2026$34Mar 6, 2026$35Mar 20, 2026$42Apr 2, 2026$46Apr 17, 2026$51May 1, 2026$56May 15, 2026$69May 29, 2026$83Jun 12, 2026$87Jun 26, 2026$92Jul 10, 2026$95Jul 24, 2026$111Aug 7, 2026$122Aug 21, 2026$112Sep 4, 2026$110Sep 18, 2026$116Oct 2, 2026$110Oct 16, 2026$81Oct 30, 2026$73Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • We expect our growth to continue and are reiterating our 2026 revenue guidance of $1.1 billion to $1.2 billion.

    Atabak Mokari · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Corcept Therapeutics (CORT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Weak
Growth Durability Strong
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Corcept Therapeutics (CORT), and what does it report?

Short answer · as of

Corcept is a commercial pharmaceutical company built around cortisol modulation, not a development-stage biotechnology company waiting for initial product revenue. Korlym is its primary marketed treatment, prescribed for hyperglycemia caused by hypercortisolism in eligible adults with endogenous Cushing’s syndrome when surgery has failed or is unsuitable.

Reported revenue therefore measures principally the commercialization of Korlym, while research spending supports relacorilant and other selective cortisol modulators across endocrine and oncology indications. This combination produces the unusual reporting shape: established product revenue and profit alongside research expenditure that remains large relative to operating income.

2 · Latest results

What do the latest results show for Corcept Therapeutics (CORT)?

The latest period reversed the preceding contraction: revenue rebounded sharply, the operating loss became a profit, and operating cash flow returned to positive territory. Research expense eased from the prior period, but selling and administrative expense continued climbing; Corcept’s exceptionally high gross margin allowed much of the revenue recovery to reach operating profit despite that heavier commercial cost base.

Recent earnings have been volatile and revenue had repeatedly fallen short of market estimates before the latest result exceeded expectations. Management subsequently raised its revenue outlook and said it expects growth to continue, but that statement is guidance rather than evidence that the latest acceleration will persist.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$340.47M Sep 30, 2026
Latest quarter · R&D
$56.71M Sep 30, 2026
Latest quarter · SG&A
$164.43M Sep 30, 2026
Latest quarter · FMP standardized operating result
$114.72M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$340.47M$56.71M$164.43M$114.72M
Jun 30, 2026$256.15M$53.89M$156.90M$41.30M
Mar 31, 2026$164.90M$66.27M$145.36M−$49.60M
Dec 31, 2025$202.13M$64.86M$130.24M$4.49M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$340.47M Nov 3, 2026
Latest report · revenue estimate
$339.13M Nov 3, 2026
Latest report · revenue vs estimate
Above estimate Nov 3, 2026
Latest report · EPS vs estimate
Above estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$340.47M$339.13M$1.0100$0.8400
Jul 29, 2026$256.15M$221.15M$0.3600$0.0243
Apr 30, 2026$164.90M$185.27M−$0.3000−$0.1102
Feb 24, 2026$202.13M$254.94M$0.2000$0.3300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$208M$20M$0.16 (diluted)
Q4 FY2025$202M$24M$0.20 (diluted)
Q1 FY2026$165M-$32M-$0.30 (diluted)
Q2 FY2026$256M$43M$0.36 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Corcept Therapeutics (CORT)?

Short answer

Cash and short-term investments were $370.70M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $142.89M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Corcept carries substantial cash and short-term investments, minimal debt, and liquidity ratios that indicate ample coverage of near-term obligations. The marketed business has generated annual profit and operating cash flow has usually remained positive, while capital expenditure is modest.

The cash balance nevertheless ended the reported window below its opening level. More important, current economics remain concentrated in Korlym while research and commercial expenses consume a large share of gross profit; weaker Korlym demand would therefore pressure earnings and internal pipeline funding at the same time. The market value stands far above net cash, so balance-sheet strength offers limited protection against a reassessment of expected growth.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Rich valuation — a P/E of 46.71 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$142.89M Sep 30, 2026
Previous quarter · operating cash flow
$33.54M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$142.89M−$710,000
Jun 30, 2026$33.54M−$2.53M
Mar 31, 2026−$16.77M−$200,000
Dec 31, 2025$38.45M−$50,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Corcept Therapeutics (CORT)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027.

At the scheduled earnings release, compare revenue with the elevated market estimate and examine whether operating profit and cash generation hold as selling and administrative spending expands. Confirmation would be continued revenue strength with positive operating cash flow; renewed revenue weakness alongside rising expenses would challenge the latest recovery.

Management’s raised outlook also needs support from reported sales rather than guidance alone. Beyond the near-term result, the widening range of longer-horizon revenue estimates shows that expectations depend heavily on how far Corcept can extend its cortisol franchise, making progress around relacorilant commercially consequential.

What management is planning

Management's statement is quoted under Upcoming events

5 · Peer comparison

How does Corcept Therapeutics compare with its peers?

Short answer

Corcept Therapeutics's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Corcept sits between a mature specialty-drug company and a pipeline-focused biotechnology business. Korlym already supports high gross profit, annual earnings, and internal cash generation, while relacorilant and other cortisol modulators create development optionality without making the company dependent on external financing for routine operations.

That profile differs from a diversified pharmaceutical company because current commercial exposure is concentrated in Korlym and much of the pipeline remains tied to cortisol biology. It also differs from a pre-commercial peer because product demand, commercial spending, and operating cash flow already determine near-term results. Investors are therefore evaluating execution in an existing Cushing’s franchise together with the prospect of broader endocrine and oncology uses.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
BeOne Medicines Ltd. (ONC) Same industry, near in market value$403.60 Nov 18, 2026$46.1B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Named competitor$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Corcept Therapeutics (CORT) — this page$67.79$7.42B91
Cullinan Therapeutics, Inc. (CGEM) Same industry, near in market value$9.01 Nov 18, 2026$585M51 5-pillar Nov 18, 2026
Galecto, Inc. (DMRA) Same industry, near in market value$22.98 Nov 18, 2026$1.42B50 5-pillar Nov 18, 2026
Jazz Pharmaceuticals plc (JAZZ) Named competitor$247.77 Nov 18, 2026$15.9B40 5-pillar Nov 18, 2026
High Tide Inc. (HITI) Same industry, near in market value$2.37 Nov 18, 2026$211M36 5-pillar Nov 18, 2026
Axsome Therapeutics, Inc. (AXSM) Named competitor$134.00 Nov 18, 2026$7.05B34 5-pillar Nov 18, 2026
Satellos Bioscience Inc. Common Stock (MSLE) Same industry, near in market value$5.94 Nov 18, 2026$126M32 5-pillar Nov 18, 2026
Rein Therapeutics, Inc. (RNTX) Same industry, near in market value$0.36 Nov 18, 2026$30.7M30 5-pillar Nov 18, 2026
PetMed Express, Inc. (PETS) Same industry, near in market value$0.90 Nov 18, 2026$20.0M29 5-pillar Nov 18, 2026
LifeMD, Inc. (LFMDP) Same industry, near in market value$19.24 Nov 18, 2026$133M22 5-pillar Nov 18, 2026
Pomdoctor Limited (POM) Same industry, near in market value$1.61 Nov 18, 2026$57.9M21 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$50.00 – $165.00
Consensus target
$132.80
Median target
$150.00

Consensus record · Captured .

Measured against a quoted price of $67.79 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026

Transactions
55
Identified insiders
7
Purchases
0
Sales
25
Other transactions
30

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
76.0% Period end Sep 30, 2026
Previous quarter · ownership
79.3% Prior to period end Sep 30, 2026
Reporting holders
525 Period end Sep 30, 2026
Previous quarter · holders
451 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.10,195,060
Ingalls & Snyder LLC7,667,798
Renaissance Technologies LLC4,850,083
Vanguard Portfolio Management LLC4,777,065
Vanguard Capital Management LLC4,353,398

Tracked investors

Which of the 16 named investors we follow held CORT in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.13%$30.90MAdded +365.6% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Corcept Therapeutics (CORT)?

Read these with our analysis →

Common Questions About CORT (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Is Korlym still Corcept’s commercial engine?

Korlym remains Corcept’s primary commercial offering, so reported revenue principally reflects demand for its use in eligible adults with Cushing’s syndrome. The pipeline broadens the opportunity set but does not yet replace Korlym as the foundation of current economics.

How could relacorilant change Corcept’s business?

Relacorilant is being developed for Cushing’s syndrome and, with nab-paclitaxel, for advanced ovarian tumors. Successful commercialization could reduce reliance on Korlym and extend Corcept’s cortisol-modulation franchise into oncology.

Why did Corcept return to profit after its recent loss?

Revenue recovered sharply while research expense eased, more than offsetting continued growth in selling and administrative costs. Corcept’s very high gross margin amplified the effect of that revenue rebound on operating profit and cash flow.

Can Korlym fund Corcept’s cortisol-modulator pipeline?

The marketed business has produced annual profit and generally positive operating cash flow, while substantial liquidity and minimal debt provide additional capacity. Rising research and commercial expenses mean that continued Korlym demand remains important to preserving that self-funded model.

What is the CORT stock price today?

The last price recorded for Corcept Therapeutics Incorporated (CORT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CORT price target?

The analyst consensus price target for Corcept Therapeutics Incorporated (CORT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 2 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Analyst revenue and earnings estimates (average)
  • 1. What is Corcept Therapeutics (CORT), and what does it report?: Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Corcept Therapeutics (CORT)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for Corcept Therapeutics (CORT)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Business description; Annual revenue and net result (USD millions)
  • 4. What should you watch next at Corcept Therapeutics (CORT)?: Next earnings report; Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Business description
  • 5. How does Corcept Therapeutics compare with its peers?: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Trailing twelve-month ratio set; Analyst revenue and earnings estimates (average)
  • FAQ: Is Korlym still Corcept’s commercial engine?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: How could relacorilant change Corcept’s business?: Business description; Analyst revenue and earnings estimates (average)
  • FAQ: Why did Corcept return to profit after its recent loss?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Reported versus estimated, last 8 quarters
  • FAQ: Can Korlym fund Corcept’s cortisol-modulator pipeline?: Business description; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Quarterly income statement (USD thousands)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.